Categories, n (%)* | MTX monotherapy (n=314) | ADA 40 mg EOW + MTX (n=579) | Any UPA 15 mg QD (n=3209) | Any UPA 30 mg QD (n=1204) |
Total patients with ≥1 HZ event | 5 (1.6) | 11 (1.9) | 204 (6.4) | 150 (12.5) |
Single dermatome | 5 (100) | 9 (81.8) | 153 (75.0) | 110 (73.3) |
Ophthalmic involvement | 0 | 2 (18.2) | 13 (6.4) | 3 (2.0) |
Meningoencephalopathic involvement | 0 | 0 | 0 | 1 (0.7) |
Unilateral involving multiple dermatomes† | 0 | 0 | 35 (17.2) | 27 (18.0) |
HZ oticus (Ramsay Hunt syndrome) | 0 | 0 | 2 (1.0) | 1 (0.7) |
Disseminated, cutaneous only (no CNS involvement)‡ | 0 | 1 (9.1) | 12 (5.9) | 11 (7.3) |
Disseminated with other non-cutaneous organ involvement (no CNS involvement)§ | 0 | 0 | 0 | 0 |
Postherpetic neuralgia¶ | 0 | 1 (8.3) | 17 (7.2) | 13 (7.2) |
Hospitalisations because of HZ event¶ | 0 | 0 | 11 (4.7) | 15 (8.3) |
Missing | 0 | 0 | 5 (2.5) | 2 (1.3) |
*Patients may fall into >1 category.
†≤2 adjacent dermatomes.
‡≥3 dermatomes, unilateral non-adjacent dermatomes or bilateral dermatomes.
§Involvement of visceral organs (eg, HZ pneumonia or HZ hepatitis).
¶Percentages based on total number of HZ events.
ADA, adalimumab; CNS, central nervous system; EOW, every other week; HZ, herpes zoster; MTX, methotrexate; QD, once daily; UPA, upadacitinib.